Aurobindo Pharma share price was trading flat on March 12 after the company's subsidiary received WHO GMP approval. At 09:56 am Aurobindo Pharma was quoting at Rs 1,063.90, down Rs 0.45, or 0.04 percent, on the BSE. The Prequalification Unit Inspection Team (PQT-INS) of the World Health organization (WHO) had inspected the Unit IV, a formulation manufacturing facility of a wholly owned subsidiary, APL Healthcare, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, between September 11 and September 15, 2023. Based on the inspection findings and our response to the same, the PQT-INS has decided to recommend to the Prequalification Assessment Team that the above facility be named as a manufacturing site in the dossier for Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate Tablets (50/300/300 mg), the company said.